Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery

Since the annual J.P. Morgan Healthcare Conference in San Francisco in early January, biotech has seen a notable surge in enthusiasm, Zahid Moneer, senior managing director of investment banking at BNP Paribas, told The BioCentury Show.
Moneer, who is more upbeat than many in today’s biopharma sector, sees capital raises from million-dollar seed rounds to nine-digit series A, B, and C rounds driving significant growth alongside M&A activity. In the interview, he also also highlights the growing role of private equity firms in biopharma and the trend of pharmas engaging earlier with biotechs and investors looking to deploy capital into those companies

View full story: https://www.biocentury.com/article/655216

#biotech #biopharma #pharma #lifescience #financing #privateequity #IPO

00:00 - Introduction
00:37 - Investment Climate
05:06 - Pharma M&A Activity
15:25 - Private Equity's Role
21:44 - Biotech Financing